

**THE PROMIUS PROMISE
NOW OFFERS EVEN MORE . . .**

***Trianex® 0.05% (Triamcinolone Acetonide Ointment, USP)
Ointment, Cloderm® Cream, 0.1% (clocortolone pivalate)
and Clocortolone Pivalate Cream, 0.1% are Covered***

Princeton, NJ – June 1, 2015 – **The Promius Promise**, a program created by Promius Pharma LLC in 2013, designed specifically to support patients, has been expanded to include **Cloderm® Cream, 0.1%, Clocortolone Pivalate Cream, 0.1%** and **Trianex® 0.05% (triamcinolone Acetonide Ointment,USP)**. The program is designed to help improve patient and physician experiences by increasing patient education and reducing eligible patient out of pocket expenses.

“We reviewed the success of The Promius Promise over the past two years and have been told by healthcare providers and patients alike that the program has substantial value,” explained Eric Shenloogian, Associate Director of Marketing for Promius. “It seemed logical to extend the program benefits across more Promius brands.”

Highlights of The Promius Promise include a dedicated call center staff which can educate patients about their insurance coverage and answer any questions they might have about their required out of pocket cost. Point of Sale rebates will be automatically applied for all eligible patients and the call center will answer any questions patients may have about Co-Pay Assistance and Prior Authorizations.

Gaining access to needed medication is of primary importance to patients, but these days there can be so many extra layers to go through. The Promius Promise program can help support patients in ways other companies may not, because “Good Health Can’t Wait.”

#

About Promius Pharma, LLC

Promius Pharma is a wholly owned, branded specialty company, of Dr. Reddy’s Laboratories, Inc. It is located in Princeton, NJ. Promius Pharma is a focused, leading-edge company that develops and markets innovative solutions for challenging dermatological conditions with an eye to the future to redefine therapeutic options for physicians and patients.

For more information visit www.promiuspharma.com.

CONTACT: Suzanne Lane
Lane Communications Group
212.757.6880, slane@thelcgroup.com